Skip to main content

Advertisement

SpringerLink
Log in

RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Malignant melanoma is an increasing disease in China, and its molecular mechanisms of development and progression are limited. The objective of this study was to investigate the expression of Ras interaction/interference 1 (RIN1) protein and its clinical significance in human melanoma. Immunohistochemistry was performed to detect the expression of RIN1 in 81 melanoma patients with a 5-year follow-up. The prognosis of the patients, classified by the clinicopathologic features and RIN1 expression, was assessed by multivariate analysis. RIN1 levels were then analyzed with overall survival (OS), progression-free survival (PFS), and recurrence-free survival (RFS) in the cohort. The biological function was determined by proliferation assay, flow cytometry analysis through knocking down of RIN1 in melanoma cells A375, as well as caspase-3 activation and PARP cleavage were detected by western blot or fluorometric assay. Data showed that RIN1 was overexpressed in melanoma samples. High-level RIN1 expression was observed in 49.4 % (40 of 81 cases), associated with thickness grade (P = 0.008) and lymph node metastasis (P < 0.001). Two distinguished subgroups were segregated by RIN1 levels within this set comparing prognostication of OS, PFS, and RFS. Importantly, RIN1 level was revealed as the significant independent prognostic factor for death and progression but a weak contribution for recurrence. Moreover, knock down of RIN1 expression in A375 cells, suppressed cell proliferation and induced apoptosis through caspase-3 activation and PARP cleavage. RIN1 expression could be a potential prognostic predictor for the melanoma patients and provide a potential target therapy for melanoma treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  2. De Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma. Crit Rev Oncol Hematol. 2003;47:35–63.

    Article  PubMed  Google Scholar 

  3. Boyle GM. Therapy for metastatic melanoma: an overview and update. Expert Rev Anticancer Ther. 2011;11:725–37.

    Article  CAS  PubMed  Google Scholar 

  4. Colicelli J, Nicolette C, Birchmeier C, Rodgers L, Riggs M, Wigler M. Expression of three mammalian cDNAs that interfere with RAS function in Saccharomyces cerevisiae. Proc Natl Acad Sci USA. 1991;88:2913–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Han L, Wong D, Dhaka A, Afar D, White M, Xie W, Herschman H, Witte O, Colicelli J. Protein binding and signaling properties of RIN1 suggest a unique effector function. Proc Natl Acad Sci USA. 1997;94:4954–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, Rosenberg N, Witte ON, Colicelli J. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity. 1997;6:773–82.

    Article  CAS  PubMed  Google Scholar 

  7. Hu H, Bliss JM, Wang Y, Colicelli J. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol. 2005;15:815–23.

    Article  CAS  PubMed  Google Scholar 

  8. Cao X, Tanis KQ, Koleske AJ, Colicelli J. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms. J Biol Chem. 2008;283:31401–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Barbieri MA, Kong C, Chen PI, Horazdovsky BF, Stahl PD. The SRC homology 2 domain of Rin1 mediates its binding to the epidermal growth factor receptor and regulates receptor endocytosis. J Biol Chem. 2003;278:32027–36.

    Article  CAS  PubMed  Google Scholar 

  10. Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF. Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell. 2001;1:73–82.

    Article  CAS  PubMed  Google Scholar 

  11. Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, Park NH, Colicelli J, Gollin SM. A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer. 2000;28:153–63.

    Article  CAS  PubMed  Google Scholar 

  12. Zainabadi K, Benyamini P, Chakrabarti R, Veena MS, Chandrasekharappa SC, Gatti RA, Srivatsan ES. A 700-kb physical and transcription map of the cervical cancer tumor suppressor gene locus on chromosome 11q13. Genomics. 2005;85:704–14.

    Article  CAS  PubMed  Google Scholar 

  13. Tomshine JC, Severson SR, Wigle DA, Sun Z, Beleford DA, Shridhar V, Horazdovsky BF. Cell Proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on RIN1. J Biol Chem. 2009;284:26331–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Senda K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Analysis of RIN1 gene expression in colorectal cancer. Oncol Rep. 2007;17:1171–5.

    CAS  PubMed  Google Scholar 

  15. Wang Q, Gao Y, Tang Y, Ma L, Zhao M, Wang X. Prognostic significance of RIN1 gene expression in human non-small cell lung cancer. Acta Histochemica. doi:10.1016/j.acthis.2011.08.008

  16. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE. 2004;250:RE13.

    Google Scholar 

  17. Han L, Colicelli J. A human protein selected for interference with RAS function interacts directly with RAS and competes with Raf1. Molecular and Cellular Biology. 1995;15:1318–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wang Y, Waldron RT, Dhaka A, Patel A, Riley MM, Rozengurt E, Colicelli J. The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol. 2002;22:916–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bliss JM, Venkatesh B, Colicelli J. The RIN family of Ras effectors. Methods in enzymology. 2006;6:335–44.

    Article  Google Scholar 

  20. Bliss JM, Gray EE, Dhaka A, O'Dell TJ, Colicelli J. Fear learning and extinction are linked to neuronal plasticity through RIN1 signaling. J Neurosci Res. 2010;88:917–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Fujioka M, Goi T, Hirono Y. Cloning of a novel splicing variant of RIN1 and its expression in gastric and colon cancer. Oncol Res. 2009;17:593–9.

    Article  PubMed  Google Scholar 

  22. Chetcuti A, Aktas S, Mackie N. Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors. Pediatr Blood Cancer. 2011;57:950–7.

    Article  PubMed  Google Scholar 

  23. Samant RS, Debies MT, Shevde LA, Verderame MF, Welch DR. Identification and characterization of the murine ortholog(brms1)of breast-cancer metastasis supperssor1 (BRMS1). Int J Cancer. 2002;97:15–20.

    Article  CAS  PubMed  Google Scholar 

  24. Thai M, Ting PY, McLaughlin J, Cheng D, Muschen M, Witte ON, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 2011;25:290–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, Dry S, Colicelli J. RIN1 is a breast tumor suppressor gene. Cancer Res. 2007;67:11510–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Namura S, Zhu J, Fink K, Endres M, Srinivasan A. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci. 1998;18:3659–68.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Dermatology, Chinese PLA General Hospital, Fuxing Road, No.28, 100853, Beijing, China

    Zigang Zhao & Xin Zhang

  2. Department of Oncology, Chinese PLA General Hospital, Beijing, China

    Ping Fang

  3. Department of Dermatology, Hejian hospital of Hebei province, Heijan, China

    Hongfang Tian

Authors
  1. Ping Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zigang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongfang Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xin Zhang.

Additional information

Ping Fang and Xin Zhang have contributed equally to the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fang, P., Zhao, Z., Tian, H. et al. RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma. Tumor Biol. 33, 1511–1518 (2012). https://doi.org/10.1007/s13277-012-0402-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0402-7

Keywords

Search

Navigation